Chronic fatigue syndrome: studies on skeletal muscle.
Grau, J M, Casademont, J, Pedrol, E et al. · Clinical neuropathology · 1992
Quick Summary
This study looked at muscle tissue samples from 20 ME/CFS patients to understand why muscles feel so tired and weak. The researchers found that most patients had either normal muscle tissue or only minor changes, and they did not find the patterns of inflammation typically seen in viral muscle diseases. The study also tested whether L-carnitine supplements could help patients improve over three months, but found no clinical benefit.
Why It Matters
This early muscle pathology study directly addresses a core ME/CFS symptom—muscle fatigue and weakness—by examining tissue at the microscopic level. The findings help clarify whether muscle symptoms arise from viral infection or inflammation, which is crucial for guiding treatment approaches and understanding disease mechanisms.
Observed Findings
Only 9 of 20 patients (45%) showed minor or nonspecific morphological changes on muscle biopsy; 11 patients had essentially normal muscle histology
Class I MHC molecule upregulation was absent in ME/CFS muscle tissue, distinguishing it from known viral and inflammatory myopathies
L-carnitine supplementation at high doses for three months produced no clinical improvement in this patient cohort
Muscle fatigue and weakness remain prominent clinical features despite absence of significant histopathological abnormalities
Inferred Conclusions
The nonspecific muscle pathology findings do not support a primary viral etiology for ME/CFS muscle fatigue
Muscle dysfunction in ME/CFS likely involves mechanisms beyond morphologically detectable inflammation or viral infection
L-carnitine does not appear effective as a treatment for ME/CFS symptoms in this study population
Remaining Questions
What cellular and biochemical abnormalities in muscle—beyond morphology—could explain the profound fatigue and weakness in ME/CFS patients?
Why do some ME/CFS patients show minor muscle changes while others have completely normal biopsies, and are these groups clinically distinct?
What role do metabolic dysfunction, mitochondrial impairment, or neuroendocrine factors play in ME/CFS muscle symptoms if structural pathology is minimal?
What This Study Does Not Prove
This study does not prove that ME/CFS muscle problems are not biological in origin; absence of morphological changes or classic viral markers does not exclude abnormalities in muscle metabolism, energy production, or function at other levels. The negative L-carnitine result in this small sample does not definitively rule out potential benefit in other patient subgroups or with different dosing protocols. Lack of inflammatory markers does not exclude other immune mechanisms contributing to muscle dysfunction.